Logo
x

Search

Subscribe Now

Systemic Lupus Erythematosus

Disease of the Month – Systemic Lupus Erythematosus

Disease of the Month – Systemic Lupus Erythematosus

  • September 18, 2024
PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythematosus

PharmaShots Interview: GSK’ Angela Carroll Shares Insights on First Paper to Define Disease Modification in Systemic Lupus Erythem...

  • May 11, 2022
AstraZeneca's Saphnelo (anifrolumab) Receives MHLW's Approval for the Treatment of Systemic Lupus Erythematosus

AstraZeneca's Saphnelo (anifrolumab) Receives MHLW's Approval for the Treatment of Systemic Lupus Erythematosus

  • September 28, 2021
AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Er...

  • August 2, 2021
Biogen Reports First Patient Dosing in P-III TOPAZ-1 Study of BIIB059 to Treat Systemic Lupus Erythematosus

Biogen Reports First Patient Dosing in P-III TOPAZ-1 Study of BIIB059 to Treat Systemic Lupus Erythematosus

  • June 18, 2021
AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULAR 2021

AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULA...

  • June 2, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.